AGARWALEYE

Dr. Agarwals Health Care Share Price

 

 

Invest in Dr. Agarwals Health Care with 3.62X leverage

Invest with MTF

Performance

  • Low
  • ₹507
  • High
  • ₹525
  • 52 Week Low
  • ₹327
  • 52 Week High
  • ₹568
  • Open Price₹517
  • Previous Close₹514
  • Volume148,931
  • 50 DMA₹502.57
  • 100 DMA₹488.85
  • 200 DMA₹452.64

Investment Returns

  • Over 1 Month + 1.43%
  • Over 3 Month + 4.66%
  • Over 6 Month + 23.18%
  • Over 1 Year + 27.67%

Smart Investing Starts Here Start SIP with Dr. Agarwals Health Care for Steady Growth!

Invest Now

Dr. Agarwals Health Care Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 141.8
  • PEG Ratio
  • 4.5
  • Market Cap Cr
  • 16,260
  • P/B Ratio
  • 8.4
  • Average True Range
  • 14
  • EPS
  • 3.68
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.82
  • RSI
  • 56.18
  • MFI
  • 71.96

Dr. Agarwals Health Care Financials

Dr. Agarwals Health Care Technicals

EMA & SMA

Current Price
₹513.25
-0.85 (-0.17%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹504.88
  • 50 Day
  • ₹502.57
  • 100 Day
  • ₹488.85
  • 200 Day
  • ₹452.64

Resistance and Support

515.13 Pivot Speed
  • R3 540.97
  • R2 532.98
  • R1 523.12
  • S1 505.27
  • S2 497.28
  • S3 487.42

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Dr Agarwal’s Eye Hospitals operate across 13 Indian states and 3 Union Territories, with a flagship center in Chennai. Internationally, the group spans 9 African countries. They offer advanced treatments for cataracts, glaucoma, retina, cornea, and pediatric ophthalmology.

Dr. Agarwal's Health Care Ltd has an operating revenue of Rs. 1,877.05 Cr. on a trailing 12-month basis. An annual revenue growth of 28% is outstanding, Pre-tax margin of 9% is okay, ROE of 4% is fair but needs improvement. The company has a reasonable debt to equity of 8%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 14% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 9% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 61 which is a FAIR score but needs to improve its earnings, a RS Rating of 80 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 81 indicates it belongs to a poor industry group of Medical-Hospitals and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Dr. Agarwals Health Care Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-10-30 Quarterly Results
2025-08-12 Quarterly Results
2025-05-28 Audited Results
2025-02-14 Quarterly Results

Dr. Agarwals Health Care F&O

Dr. Agarwals Health Care Shareholding Pattern

32.42%
5.85%
1.33%
20.11%
0%
1.41%
38.88%

Dr. Agarwals Health Care FAQs

Dr. Agarwals Health Care share price is ₹513 As on 08 January, 2026 | 05:28

The Market Cap of Dr. Agarwals Health Care is ₹16260.1 Cr As on 08 January, 2026 | 05:28

The P/E ratio of Dr. Agarwals Health Care is 141.8 As on 08 January, 2026 | 05:28

The PB ratio of Dr. Agarwals Health Care is 8.4 As on 08 January, 2026 | 05:28

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23